Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to its new drug application for zongertinib (BI 1810631) for the treatment of adult ...

Ingelheim: Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to ...

Dr. Debu Tripathy breaks down the FDA approval of Enhertu in unresectable or metastatic HR-positive, HER2-low or -ultralow ...

Laboratory Illustrative image Ridgefield, Conn., U.S., and Ingelheim, Germany Zongertinib would be the first orally ...

Pluripotent stem cells are cells that have the capacity to self-renew by dividing and to develop into the three primary germ cell layers of the early embryo and therefore into all cells of the ...

Level Zero Health, a female-founded medical device startup that's aiming to break new ground by developing a device for ...

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

Several weeks after reporting positive results for nerandomilast for idiopathic pulmonary fibrosis, Boehringer Ingelheim ...

The University of Konstanz and Chinese panel maker Longi have assessed the impact of gettering on LeTID in industrial ...

Blood clots form in response to signals from the lungs of cancer patients -- not from other organ sites, as previously thought -- according to a preclinical study. Clots are the second-leading cause ...

Blood clots form in response to signals from the lungs of cancer patients—not from other organ sites, as previously thought—according to a preclinical study by Weill Cornell Medicine, Memorial Sloan ...